Former employees of Alphabets's Verily life sciences division say its signature projects are plagued by serious scientific shortcomings
MOUNTAIN VIEW, Calif. — Google employees, squeezed onto metal risers and standing in the back of a meeting room, erupted in cheers …
Context & Ripple Effects
A month after Google renamed its Life Sciences division as Verily and began positioning it as one of Alphabet's flagship "Other Bets," STAT is reporting that former employees of the unit say its signature projects suffer from serious scientific shortcomings. The critique lands just as Verily is rolling out a new compensation structure — stock tied to division-level performance — that makes employee belief in the science directly financial.
Read against the decade of coverage since, this report reads as an early warning: the unit went on to cut more than 200 jobs in 2023, close its Israeli R&D centers in 2024, end its medical devices program outright in 2025, and spend two years being technologically decoupled so Alphabet can sell or spin it off.
First-order effects
- Verily's recruiting and retention case weakens at exactly the moment its new division-performance stock makes employees' payouts depend on the very projects now being called scientifically shaky.
Second-order effects
- Alphabet faces pressure to prove its Other Bets are more than engineering ambition without scientific rigor — a credibility test that lands on every moonshot division sharing the Verily structure.
Third-order effects
- If the pattern holds, Alphabet's life sciences bet contracts from building consumer-facing devices toward data- and AI-centric precision health, ending in a divestiture rather than a second act inside the company.
The trend: Alphabet's moonshot divisions are being disciplined by scientific and commercial reality, with Verily shrinking from device-building to a data-and-AI unit positioned for sale or spinoff.